[Market Watch] CVS officials say Sovaldi pricing in line with history, but unsustainable

Jul 20, 2014

Gilead Sciences’ controversial $1,000-a-day Sovaldi pill is priced in line with previous treatments for Hepatitis C, but the nation’s health-care system likely won’t be able to handle that kind of sticker shock, and competition probably will bring down that price tag in coming months and years.

[button title=”Read More” link=”http://blogs.marketwatch.com/health-exchange/2014/07/20/cvs-officials-say-sovaldi-pricing-in-line-with-history-but-unsustainable/” target=”_blank” size=”” color=”” class=””]